Jun 18, 2020 / 07:00PM GMT
Reni John Benjamin - JMP Securities LLC, Research Division - MD & Equity Research Analyst
Excellent. Good afternoon, everyone, and welcome to the fireside chat with Incyte Corporation. It's my pleasure to introduce Hervé, Christiana and Peter from Incyte. As they know, and I've been telling our investors, we never know who is involved, who is listening in, whether they know Incyte or not, so I'd love to take, call it, 2 to 4 minutes, Hervé, if you can, just give us a good global sketch of what Incyte is about.
HervéHoppenot - Incyte Corporation - Chairman, President & CEO
Okay. Yes. No, thank you for the invitation. And I mean describing Incyte in 4 minutes is a little bit challenging. But basically, the whole idea behind Incyte is that discovering new products can translate into changes in the practice of medicine, obviously, and create a very fast-growing and diversified portfolio for the future in our case.
So we are a company that is heavily inclined into doing drug discovery and drug development. We have now received FDA
Incyte Corp at JMP Securities Life Sciences Conference Transcript
Jun 19, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers